| CARGO Therapeutics (NASDAQ: CRGX) | CAR-T; Oncology | JPM Securities, Jefferies, Cowen & Co., Truist Securities | 11/09/2023 S-1 | $15.00 | $281.25 million | $15 – $17 |
| Lexeo Therapeutics (NASDAQ: LXEO) | Alzheimer’s and Cardiovascular Diseases | JPM Securities, Leerink, Stifel, RBC Capital Markets | 11/02/2023 S-1 | $11.00 | $100 million | $13 – $15 |
| Abivax SA (NASDAQ: ABVX) | Therapeutics; Chronic Inflammatory Diseases | Morgan Stanley, Leerink, LifeSci Capital, RBC Capital Markets | 10/19/2023 F-1 | $11.60 | $216.91 million | $11.60 – $13 |
| Neumora Therapeutics (NASDAQ: NMRA) | Neuroscience Drug Development | JPM Securities, BofA Securities, Stifel, Guggenheim, RBC Capital Markets, William Blair & Co. | 09/14/2023 S-1 | $17.00 | $250.7 million | $16 – $18 |
| RayzeBio, Inc. (NASDAQ: RYZB) | Radiopharmaceutical Medicines; Oncology | JPM Securities, Jefferies, Evercore Group, Truist Securities | 09/14/2023 S-1 | $18.00 | $311 million | $16 – $18 |
| Turnstone Biologics (NASDAQ: TSBX) | Solid Tumors; Tumor Infiltrating Lymphocytes (TIL) | BofA Securities, Piper Sandler, Leerink Partners | 07/20/2023 S-1 | $12.00 | $80 million | $12 – $14 |
| Sagimet Biosciences Inc. (NASDAQ: SGMT) | Non-Alcoholic Steatohepatitis (NASH), Acne and Various Cancers; Inhibitors | Goldman Sachs, Cowen & Co., Piper Sandler, JPM Securities | 07/13/2023 S-1 | $16.00 | $85 million | $15 – $17 |
| Apogee Therapeutics, Inc. (NASDAQ: APGE) | Pulmonary and Inflammatory Diseases; Biologics | Jefferies, Cowen & Co., Stifel, Guggenheim, Wedbush Securities | 07/13/2023 S-1 | $17.00 | $300.5 million | $15 – $17 |
| ACELYRIN, INC. (NASDAQ: SLRN) | Transformative Medicines | Morgan Stanley, Jefferies, Cowen & Co., Piper Sandler | 05/04/2023 S-1 | $18.00 | $540 million | $16 – $18 |
| Mineralys Therapeutics, Inc. (NASDAQ: MLYS) | Hypertension and Cardiovascular Diseases | BofA Securities, Evercore, Stifel, Guggenheim, Credit Suisse, Wells Fargo | 02/09/2023 S-1 | $16.00 | $192 million | $14 – $16 |
| Structure Therapeutics Inc. (NASDAQ: GPCR) | Chronic Diseases; Oral Therapeutics | Jefferies, SVB Securities, Guggenheim, BMO Capital Markets | 02/02/2023 S-1 | $15.00 | $161.1 million | $13 – $15 |
